Metagenomi Therapeutics (MGX) EBITDA Margin (2023 - 2026)
Metagenomi Therapeutics (MGX) reported EBITDA Margin of 1872.04% for Q1 2026, down 126319.0% year-over-year from N/an in Q1 2025, and down 223.4% quarter-over-quarter from 578.85% in Q4 2025.
Metagenomi Therapeutics (MGX) EBITDA Margin (2023 - 2026) Analysis & Trends
Metagenomi Therapeutics (MGX) has 4 years of EBITDA Margin data on file, last reported at 1872.04% in Q1 2026.
- EBITDA Margin for Q1 2026 came in at 1872.04%, down 126319.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 387.59% (down 21736.0% YoY), and the FY2025 annual result was 350.33%, down 20260.0% from the prior year.
- EBITDA Margin eased to 1872.04% in Q1 2026 per MGX's latest filing, from 578.85% in the prior quarter.
- Over five years, EBITDA Margin peaked at 53.61% in Q2 2024 and troughed at 1872.04% in Q1 2026.
- A 4-year average of 371.37% and a median of 226.98% in 2024 frame the typical range for EBITDA Margin.
- The sharpest annual moves came in 2024 and 2026: EBITDA Margin jumped 6268 bps in 2024, then sank 126319 bps in 2026.
- A 4-year view of EBITDA Margin shows it stood at 153.5% in 2023, then tumbled by 65 bps to 253.05% in 2024, then tumbled by 129 bps to 578.85% in 2025, then sank by 223 bps to 1872.04% in 2026.
- Business Quant data shows MGX's EBITDA Margin at 1872.04% in Q1 2026, 578.85% in Q4 2025, and 235.52% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 821,726.73 Bn | 821,726.69 Bn | - | - |
| 2 | Belite Bio | 57,768.00 Bn | 57,768.00 Bn | - | - |
| 3 | Quantum Biopharma | 16,655.88 Bn | 16,655.88 Bn | - | - |
| 4 | Legend Biotech | 3,540.00 Bn | 3,539.71 Bn | 242.10 Mn | -6.43% |
| 5 | Evaxion A | 1,526.26 Bn | 1,526.24 Bn | - | - |
| 6 | Akari Therapeutics | 1,520.09 Bn | 1,520.09 Bn | - | - |
| 7 | Psyence Biomedical | 223.87 Bn | 223.87 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.47 Bn | 107.23 Bn | 2.59 Bn | 38.10% |
| 9 | Abivax | 91.22 Bn | 91.22 Bn | - | - |
| 10 | Metagenomi Therapeutics | 42.84 Mn | 42.84 Mn | - | -1,872.04% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1,872.04% |
| Dec 31, 2025 | -578.85% |
| Sep 30, 2025 | -235.52% |
| Jun 30, 2025 | -236.78% |
| Mar 31, 2025 | -608.84% |
| Dec 31, 2024 | -253.05% |
| Sep 30, 2024 | -146.51% |
| Jun 30, 2024 | -53.61% |
| Mar 31, 2024 | -226.98% |
| Dec 31, 2023 | -153.50% |
| Sep 30, 2023 | -159.75% |
| Jun 30, 2023 | -116.29% |
| Mar 31, 2023 | -186.12% |